Select Fourth Quarter 2023 Highlights and Preliminary Unaudited Revenue: Placed six new Growth Direct systems; Growth Direct platform selected by Samsung Biologics to automate microbiology quality control testing; Growth Direct systems now placed with 100% of commercially approved CAR-T therapy manufacturers; Completed nine validations; Cash, cash equivalents and investments of approximately $95 million as of December 31, 2023; cash runway at least into the second half of 2026. The Company currently expects total revenue of between $6.2 million and $6.4 million in the fourth quarter of 2023, representing growth of approximately 45% compared to the prior-year period.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RPID:
- Rapid Micro announces Samsung Biologics selected its Growth Direct platform
- Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing
- Rapid Micro Biosystems to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Rapid Micro Biosystems files $200M mixed securities shelf
